Discovering transformational therapies

Mission

KnotBody®

Inspired by nature,
enhanced by innovation.

KnotBody® Technology

Using our revolutionary KnotBody® technology, we are creating first-in-class and best-in-class protein therapeutics for treating previously untreatable ion channel and GPCR-driven diseases.

Antibody based drugs can be a game changer

maxion-therapeutics-GPRC-sillouette

Chronic Pain

maxion-therapeutics-blue-dot

It affects ~1.5 billion people worldwide and ~64% of patients on the current pain medications are inadequately treated.

Autoimmunity

maxion-therapeutics-purple-dot

More than 300 million people worldwide suffer from autoimmune disorders.

Cardiovascular disease

maxion-therapeutics-light-blue-dot

Cardiovascular disease is the leading cause of death globally.

Ion channel and GPCR disfunction are implicated in a wide range of debilitating diseases and current treatments based on small molecule drugs suffer from poor efficacy and side effects.

Compared to small molecules, engineered antibodies offer vastly superior selectivity and are well proven therapeutically, representing 7/10 of top-selling drugs.

Despite these obvious advantages, antibody discovery against ion channel and GPCRs has been challenging.

Opportunity

Technology

Natural evolution meets directed evolution.

KnotBody®

Inspired by nature

By fusing naturally occurring cysteine-rich miniproteins (‘Knottins’) into antibody binding loops, our patented KnotBody® technology combines the power of millions of years of Knottin evolution in targeting ion channels and GPCRs with state-of-the-art antibody engineering techniques, addressing key challenges in ion channel and GPCR drug discovery.

KnotBody®

Enhanced by innovation

Multifunctionality

Potency and Selectivity

Half-life & Manufacturability

Multifunctionality

Potency & Selectivity

Half-life & manufacturability

We are leveraging this technology to deliver safe, efficacious and long-acting drugs against previously undruggable targets.

Executive Directors

Maxion is founded and led by an experienced team with an excellent track record.

Arndt Schottelius, MD, PhD

CEO

Read more

John McCafferty, PhD

Co-founder and CTO

Read more

Aneesh Karatt-Vellatt, PhD

Co-founder and CSO

Read more

Non-Executive Directors

Eva-Lotta Allan

Independent Chair

Read more
Thomas Weaver_maxion

Thomas Weaver, PhD

Non-Executive Director
CEO Petmedix

Read more

Dr Tim Funnell

Partner
Monograph Capital

Read more

Lucy Edwardes Jones

Investor
BGF

Read more

Dr Sohaib Mir

Senior Investment Principal
LifeArc Ventures

Read more

The Works, Suite 4 — Unity Campus
London Road
Cambridge, CB22 3FT
United Kingdom

Primary logo positive

Contact